应用人同种异体外周血LAK细胞治疗38例晚期恶性肿瘤患者的疗效观察  

Allogeneic LAK Cells in Adoptive Immunotherapy of Advanced Cancers. A Repot on 38 Cases

作　　者：田志刚[1] 明雨[1] 张建华[1] 张燕[1] 刘杰[1] 孙汭[1] 张捷[1] 田彤[1] 崔正言[1] 陈黎 王媛[3] 

机构地区：[1]山东省医学科学院山东肿瘤生物治疗中心,济南市250001 [2]山东省肿瘤防治病院 [3]山东省医学科学院临床部

出　　处：《中国肿瘤临床》1994年第1期13-16,共4页Chinese Journal of Clinical Oncology

摘　　要：为了探索一种新的IL—2/LAK治疗方案,本研究采用rIL—2和自行设计的工艺制备的人同种异体LAK细胞,按“3W”方案,治疗多种晚期恶性肿瘤患者共38例.结果表明,多数患者自觉症状有改善,生活质量提高,部分患者的癌性症状改善明显,38例患者中,CR3例(7.9%),PR14例(36.8%).作者认为该疗法与国外同类方法相比,制备工艺简便,LAK细胞获取量大,治疗效果肯定,副作用轻,具有一定的推广应用价值.Lymphocytes isolated from normal human peripheral blood can be expanded on a large scale according to the technic elaborated by us. The results observed in the 38 cases of various advanced cancers treated by adoptive im-munotherapy with the allogeneic LAK cell and rIL-2 are reported. Of the 38 patients 3 had complete and 14 partial responses. It appears that the '3 weeks(3w)'regimen adopted in this therapy is safer.more efficacious,especially more suitable for advanced cancer patients.

关 键 词：肿瘤 免疫疗法 杀伤细胞 癌 

分 类 号：R730.51[医药卫生—肿瘤]